Survival Outcomes of Breast-Conserving Therapy versus Mastectomy in Early-Stage Breast Cancer, Including Centrally Located Breast Cancer: A SEER-Based Study
Table 4
Comparison of baseline characteristics between CLBC patients undergoing BCT and mastectomy from 2000 to 2015.
Mastectomy
BCT
-value
N
%
N
%
Year
0.063
2000–2003
1388
22.4%
1214
20.7%
2004–2007
1447
23.4%
1382
23.6%
2008–2015
3352
54.2%
3268
55.7%
Age, years
<0.001
18–63
3866
62.5%
3560
60.7%
64–72
1390
22.5%
1500
25.6%
73–79
931
15.0%
804
13.7%
Race
<0.001
White
4942
79.9%
4894
83.5%
Black
506
8.2%
485
8.3%
Others
739
11.9%
485
8.3%
Histological type
<0.001
IDC
5582
90.2%
5436
92.7%
ILC
605
9.8%
428
7.3%
Laterality
0.357
Left
3157
51.0%
2943
50.2%
Right
3030
49.0%
2921
49.8%
Grade
I
999
16.1%
1439
24.5%
II
2934
47.4%
2862
48.8%
III/IV
2254
36.4%
1563
26.7%
T stage
<0.001
T1a
415
6.7%
611
10.4%
T1b
770
12.4%
1400
23.9%
T1c
2179
35.2%
2521
43.0%
T2
2823
45.6%
1332
22.7%
N stage
<0.001
N0
3871
62.6%
4286
73.1%
N1
1860
30.1%
1350
23.0%
N2
310
5.0%
163
27.8%
N3
146
2.4%
65
1.1%
ER
<0.001
Negative
1025
16.6%
724
12.3%
Positive
5162
83.4%
5140
87.7%
PR
<0.001
Negative
1824
29.5%
1389
23.7%
Positive
4363
70.5%
4475
76.3%
Chemotherapy
<0.001
No or unknown
3451
55.8%
3476
59.3%
Yes
2736
44.2%
2388
40.7%
CLBC, centrally located breast cancer; BCT, breast-conserving therapy; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor.